Caribou Biosciences(CRBU)
Focus: Caribou Biosciences is a public biotech company focused on cellular engineering tools and CRISPR-based gene therapy, headquartered in Berkeley, CA. Founded in 2015, the company is advancing early-stage allogeneic CAR-T therapeutics for hematologic malignancies and autoimmune diseases.
Profile data last refreshed 36m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
4+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Caribou Biosciences?
AI assessmentCaribou offers frontier science and equity optionality but carries acute financial and pipeline risk; suitable only for risk-tolerant scientists betting on CRISPR-CAR-T success over next 3-5 years.
Why Work Here
- Access to cutting-edge CRISPR cellular engineering platform at the foundation of next-generation immunotherapy development
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$10M
Pipeline & Clinical Trials
Caribou-sponsored investigational therapy
Lymphoma, Non-HodgkinClinical Trials (1)
NCT05332054Long-Term Follow-up Study
N/AHelp build intelligence for Caribou Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.